ENDRA Life Sciences to Report First Quarter 2021 Financial Results on May 17, 2021

Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced it will report its first quarter 2021 financial results on May 17, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and recent corporate developments. ENDRA is known for its Thermo Acoustic Enhanced UltraSound (TAEUS®), a cost-effective ultrasound technology aimed at assessing liver conditions affecting over 1 billion individuals worldwide. More information can be found on their website.

Positive

• ENDRA will host a call discussing financial results, potentially offering insights into corporate strategy.
• TAEUS® technology is pioneering and addresses significant unmet needs in liver disease diagnostics.

Negative

• None.

ANN ARBOR, MI / ACCESSWIRE / May 6, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the first quarter of 2021 on Monday, May 17, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions. Participation instructions are as follows:

Dial-in Numbers
U.S./Canada: 888-506-0062
International: 973-528-0011

Replay Dial-in Numbers
U.S./Canada: 877-481-4010
International: 919-882-2331
Replay Passcode: 40908
The telephone replay will be available through 4:30 p.m. Eastern time on May 24, 2021.

Webcast
A live audio webcast will be available through the Events & Presentations page of the Investors section of the company's website at www.endrainc.com.
A replay of the webcast will be available on the website for 60 days.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology that mirrors some applications similar to CT or MRI, but at 50x lower cost and at the point of patient care. TAEUS^® is designed to work in concert with one million ultrasound systems in global use today. TAEUS^® is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures.www.endrainc.com.

Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com

SOURCE: ENDRA Life Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/644931/ENDRA-Life-Sciences-to-Report-First-Quarter-2021-Financial-Results-on-May-17-2021

FAQ

When will ENDRA Life Sciences report its first quarter 2021 financial results?

ENDRA Life Sciences Inc. will report its first quarter 2021 financial results on May 17, 2021.

What is the purpose of the conference call scheduled for May 17, 2021?

The conference call will discuss the financial results and provide an update on recent corporate developments.

What unique technology does ENDRA Life Sciences offer?

ENDRA Life Sciences offers Thermo Acoustic Enhanced UltraSound (TAEUS®), which provides low-cost diagnostic capabilities for liver conditions.

How can I access the webcast for ENDRA's financial results call?

The webcast can be accessed through the Events & Presentations section of the Investors page on ENDRA's website.